Physician profile
Sandeep Viswanath
NPI 1154761328
$17,341.81
in general payments reported to CMS, 2019-2025
34 companies · $3,817 in 2025
The $3,817 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,686 · 2020: $1,119 · 2021: $2,303 · 2022: $1,714 · 2023: $2,914 · 2024: $3,789 · 2025: $3,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,449.59 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,450.82 | 2019-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $3,222.17 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,566.53 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,544.35 | 2019-2025 | Bimzelx, Cimzia, Fintepla |
| Pfizer INC. | $1,369.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,029.03 | 2019-2025 | |
| Glaxosmithkline, LLC. | $811.71 | 2020-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $746.12 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $707.52 | 2019-2025 | Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $527.50 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.63 | 2019-2025 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $314.66 | 2022-2025 | Acthar |
| Genzyme Corporation | $295.37 | 2019-2025 | |
| Radius Health, INC. | $221.62 | 2019-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $217.54 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $136.77 | 2021-2023 | Krystexxa |
| Alvogen INC | $85.66 | 2022-2024 | Teriparatide |
| Genentech USA, INC. | $77.97 | 2019-2025 | Actemra |
| Mylan Institutional INC. | $70.82 | 2023 | |
| Celgene Corporation | $64.65 | 2019 | |
| Aurinia Pharma U.S., INC. | $59.27 | 2022-2025 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $57.78 | 2021-2022 | |
| Organon LLC | $55.62 | 2023-2024 | Renflexis |
| Kyowa Kirin, INC. | $47.43 | 2024 | Crysvita |
| Ferring Pharmaceuticals INC. | $44.68 | 2019-2020 | |
| Antares Pharma, INC. | $43.04 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $37.87 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $31.86 | 2023 | Opsumit |
| Fresenius Kabi USA, LLC | $30.31 | 2023-2024 | Idacio |
| Sobi, INC | $22.96 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.59 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.73 | 2019 | |
| Almatica Pharma LLC | $17.66 | 2025 | Loreev Xr |
| Kiniksa Pharmaceuticals, LTD. | $14.71 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Viswanath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.